|
|
|
| home > white papers > Crunch Time: The Impact of Serialisation Requirements on Packaging Operations - PCI Pharma Services |
|
|
 WHITE PAPERS |
|
PCI Pharma Services
|
|
Crunch Time: The Impact of Serialisation Requirements on Packaging Operations
|
|
The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Wool packaging firm’s green scheme goes ‘beyond recycling’
An award-winning company that has spent more than 10 years innovating in
sustainable packaging has launched a scheme that it says goes ‘beyond
recycling’ – by allowing the end user to return their packaging directly
to them to be used again.
More info >> |
|
 |
White Papers |
 |
|
Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?
Eurofins BioPharma Product Testing
As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >> |
|
 |
Industry Events |
 |
Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology
27 August - 21 November 2019, Barcelona, Spain
On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >> |
|
|
|
